comparemela.com

Latest Breaking News On - Lisa hennig - Page 1 : comparemela.com

Bayer and Evotec Collaborate to Advance Precision Cardiology

Bayer and Evotec Collaborate to Advance Precision Cardiology

Christian rommelJuergen eckhardtGabriele hansenLisa hennigBayer pharmaceuticals divisionNews networkHead of researchBusiness developmentChief scientific officerMedia contact

Bayer and Evotec collaborate to advance precision cardiology

EQS-News: Evotec SE / Key word: Miscellaneous Bayer and Evotec collaborate to advance precision cardiology 30.04.2024 / 08:30 CET/CEST The issuer is solely responsible.

Volker braunHinnerk rohwedderChristian rommelJuergen eckhardtGabriele hansenLisa hennigHead of researchBayer pharmaceuticals divisionGlobal corporate communicationsDistribution servicesHead of global corporate communicationsBusiness developmentChief scientific officerMedia contactGlobal investor relationsCorporate news

Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomChristian rommelAnn pentecostLisa hennigHead of researchExecutive committeeMedia contact

Vividion Therapeutics, Inc : Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor

Vividion Therapeutics, Inc : Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Laurie shermanLisa hennigStefan klotterAleksandra rizoChristian rommelJenna goldbergVividion therapeutics incHead of researchBayer agChief executive officerExecutive committeePharmaceuticals divisionChief medical officerMedia contactDie performance strategieAssets sie

Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor

BERLIN & SAN DIEGO (BUSINESS WIRE) Feb 6, 2024

United statesJenna goldbergLaurie shermanAleksandra rizoLisa hennigChristian rommelBayer agVividion therapeutics incHead of researchChief executive officerExecutive committeePharmaceuticals divisionChief medical officerVividion media contactMedia contactVividion therapeutics

vimarsana © 2020. All Rights Reserved.